Targeted c-Myc Inhibition and Systemic Temozolomide Therapy Extend Survival in Glioblastoma Xenografts

Glioblastoma is a highly aggressive disease with poor patient outcomes despite current treatment options, which consist of surgery, radiation, and chemotherapy. However, these strategies present challenges such as resistance development, damage to healthy tissue, and complications due to the blood–b...

Descripción completa

Detalles Bibliográficos
Autores principales: Dhungel, Laxmi, Harris, Cayla, Romine, Lauren, Sarkaria, Jan, Raucher, Drazen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294868/
https://www.ncbi.nlm.nih.gov/pubmed/37370649
http://dx.doi.org/10.3390/bioengineering10060718

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294868/
https://www.ncbi.nlm.nih.gov/pubmed/37370649
http://dx.doi.org/10.3390/bioengineering10060718

Ejemplares similares